Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations.

Fujinami K, Lois N, Mukherjee R, McBain VA, Tsunoda K, Tsubota K, Stone EM, Fitzke FW, Bunce C, Moore AT, Webster AR, Michaelides M.

Invest Ophthalmol Vis Sci. 2013 Dec 17;54(13):8181-90. doi: 10.1167/iovs.13-12104.

PMID:
24265018
2.

Foveal sparing in Stargardt disease.

van Huet RA, Bax NM, Westeneng-Van Haaften SC, Muhamad M, Zonneveld-Vrieling MN, Hoefsloot LH, Cremers FP, Boon CJ, Klevering BJ, Hoyng CB.

Invest Ophthalmol Vis Sci. 2014 Oct 16;55(11):7467-78. doi: 10.1167/iovs.13-13825.

PMID:
25324290
3.

Early-onset stargardt disease: phenotypic and genotypic characteristics.

Lambertus S, van Huet RA, Bax NM, Hoefsloot LH, Cremers FP, Boon CJ, Klevering BJ, Hoyng CB.

Ophthalmology. 2015 Feb;122(2):335-44. doi: 10.1016/j.ophtha.2014.08.032. Epub 2014 Oct 17.

PMID:
25444351
4.

Cone photoreceptor abnormalities correlate with vision loss in patients with Stargardt disease.

Chen Y, Ratnam K, Sundquist SM, Lujan B, Ayyagari R, Gudiseva VH, Roorda A, Duncan JL.

Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3281-92. doi: 10.1167/iovs.10-6538.

5.

Characterization of stargardt disease using polarization-sensitive optical coherence tomography and fundus autofluorescence imaging.

Ritter M, Zotter S, Schmidt WM, Bittner RE, Deak GG, Pircher M, Sacu S, Hitzenberger CK, Schmidt-Erfurth UM; Macula Study Group Vienna.

Invest Ophthalmol Vis Sci. 2013 Sep 27;54(9):6416-25. doi: 10.1167/iovs.12-11550.

PMID:
23882696
6.

Different patterns of fundus autofluorescence related to ABCA4 gene mutations in Stargardt disease.

Sodi A, Bini A, Passerini I, Forconi S, Menchini U, Torricelli F.

Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):48-53. doi: 10.3928/15428877-20091230-09.

PMID:
20128570
7.
8.

Asymmetric Inter-Eye Progression in Stargardt Disease.

Lambertus S, Bax NM, Groenewoud JM, Cremers FP, van der Wilt GJ, Klevering BJ, Theelen T, Hoyng CB.

Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6824-6830. doi: 10.1167/iovs.16-20963.

PMID:
28002570
9.

Progression of Late-Onset Stargardt Disease.

Lambertus S, Lindner M, Bax NM, Mauschitz MM, Nadal J, Schmid M, Schmitz-Valckenberg S, den Hollander AI, Weber BH, Holz FG, van der Wilt GJ, Fleckenstein M, Hoyng CB; Foveal sparing Atrophy Study Team (FAST).

Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5186-5191. doi: 10.1167/iovs.16-19833.

PMID:
27699414
10.

Progression of retinal pigment epithelial atrophy in stargardt disease.

McBain VA, Townend J, Lois N.

Am J Ophthalmol. 2012 Jul;154(1):146-54. doi: 10.1016/j.ajo.2012.01.019. Epub 2012 Mar 30.

PMID:
22464366
11.

Clinical and molecular characteristics of childhood-onset Stargardt disease.

Fujinami K, Zernant J, Chana RK, Wright GA, Tsunoda K, Ozawa Y, Tsubota K, Robson AG, Holder GE, Allikmets R, Michaelides M, Moore AT.

Ophthalmology. 2015 Feb;122(2):326-34. doi: 10.1016/j.ophtha.2014.08.012. Epub 2014 Oct 12.

12.

The dark atrophy with indocyanine green angiography in Stargardt disease.

Giani A, Pellegrini M, Carini E, Peroglio Deiro A, Bottoni F, Staurenghi G.

Invest Ophthalmol Vis Sci. 2012 Jun 26;53(7):3999-4004. doi: 10.1167/iovs.11-9258.

PMID:
22589445
13.

Centrifugal expansion of fundus autofluorescence patterns in Stargardt disease over time.

Cukras CA, Wong WT, Caruso R, Cunningham D, Zein W, Sieving PA.

Arch Ophthalmol. 2012 Feb;130(2):171-9. doi: 10.1001/archophthalmol.2011.332. Epub 2011 Oct 10.

14.

A longitudinal study of stargardt disease: clinical and electrophysiologic assessment, progression, and genotype correlations.

Fujinami K, Lois N, Davidson AE, Mackay DS, Hogg CR, Stone EM, Tsunoda K, Tsubota K, Bunce C, Robson AG, Moore AT, Webster AR, Holder GE, Michaelides M.

Am J Ophthalmol. 2013 Jun;155(6):1075-1088.e13. doi: 10.1016/j.ajo.2013.01.018. Epub 2013 Mar 15.

PMID:
23499370
15.

Quantitative Fundus Autofluorescence and Optical Coherence Tomography in ABCA4 Carriers.

Duncker T, Stein GE, Lee W, Tsang SH, Zernant J, Bearelly S, Hood DC, Greenstein VC, Delori FC, Allikmets R, Sparrow JR.

Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7274-85. doi: 10.1167/iovs.15-17371.

16.

Fundus autofluorescence in the Abca4(-/-) mouse model of Stargardt disease--correlation with accumulation of A2E, retinal function, and histology.

Charbel Issa P, Barnard AR, Singh MS, Carter E, Jiang Z, Radu RA, Schraermeyer U, MacLaren RE.

Invest Ophthalmol Vis Sci. 2013 Aug 19;54(8):5602-12. doi: 10.1167/iovs.13-11688.

17.

Phenotypic heterogeneity and lesion size measurements in Stargardt macular dystrophy.

Shah SN, Koozekanani DD, Kim JE.

Ophthalmic Surg Lasers Imaging. 2009 Sep-Oct;40(5):506-12. doi: 10.3928/15428877-20090901-14.

PMID:
19772279
18.

Generalized choriocapillaris dystrophy, a distinct phenotype in the spectrum of ABCA4-associated retinopathies.

Bertelsen M, Zernant J, Larsen M, Duno M, Allikmets R, Rosenberg T.

Invest Ophthalmol Vis Sci. 2014 Apr 29;55(4):2766-76. doi: 10.1167/iovs.13-13391.

19.

The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.

Strauss RW, Ho A, Muñoz B, Cideciyan AV, Sahel JA, Sunness JS, Birch DG, Bernstein PS, Michaelides M, Traboulsi EI, Zrenner E, Sadda S, Ervin AM, West S, Scholl HP; Progression of Stargardt Disease Study Group.

Ophthalmology. 2016 Apr;123(4):817-28. doi: 10.1016/j.ophtha.2015.12.009. Epub 2016 Jan 16.

PMID:
26786511
20.

Quantitative fundus autofluorescence in recessive Stargardt disease.

Burke TR, Duncker T, Woods RL, Greenberg JP, Zernant J, Tsang SH, Smith RT, Allikmets R, Sparrow JR, Delori FC.

Invest Ophthalmol Vis Sci. 2014 May 1;55(5):2841-52. doi: 10.1167/iovs.13-13624.

Supplemental Content

Support Center